In the contrast to the above-mentioned data, in 2016, Ferraz-Amaro et al. [31] observed that patients with rheumatoid arthritis (RA) were shown with decreased PCSK9 concentrations than controls; however, this outcome might be influenced by simultaneously administrated tocilizumab IL-6 receptor blocker. The gene discussed is PCSK9; the disease is rheumatoid arthritis.